<DOC>
	<DOC>NCT00718380</DOC>
	<brief_summary>The objective of this study is to evaluate the pharmacokinetics, safety and tolerability of ABT-869 in Japanese patients with solid tumors up to the Recommended Phase Two Dose that was determined in a previous the M04-710 study.</brief_summary>
	<brief_title>A Phase 1 Study of ABT-869 in Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Subjects aged from 20 to 75 years and ECOG PS of 02 at screening. Subject must have a solid tumor that is refractory to standard therapies or for which a standard effective therapy does not exist. The subject must have adequate bone marrow, renal and hepatic function. Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and up to six months following completion of therapy. The subject must voluntarily sign and date an informed consent. Exclusion Criteria The subject currently exhibits symptomatic or intervention indicated CNS metastasis. The subject has received any anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic or any investigational therapy within 4 weeks of enrollment or has not fully recovered from toxicity resulting from past treatment(s) that affects the assessments in this study at the enrollment. The subject with the following conditions during screening assessment. 1. proteinuria CTC grade &gt; 1 as measured by urinalysis and 24 hour urine collection 2. diastolic blood pressure (BP) &gt; 95 mmHg; or systolic blood pressure (BP) &gt; 150 mmHg 3. a history of or currently exhibits clinically significant cancer related events of bleeding 4. LV Ejection Fraction &lt; 50% 5. received a cumulative dose of Anthracycline &gt; 360 mg/m2 for treatment of cancer 6. receiving therapeutic anticoagulation therapy 7. having fractures except for chronic bone lesion due to bone metastases The subject exhibits evidence of other clinically significant uncontrolled condition(s).</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>